CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 8, 2008--Curis, Inc. (NASDAQ: CRIS), a drug development company focused developing next generation proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the Merriman Curhan Ford 5th Annual Investor Summit 2008, which is being held on September 15-16, 2008 in San Francisco, CA. Curis' presentation will take place on Monday, September 15th at 2:45 p.m. Eastern Daylight Time (11:45 a.m. local time).
Daniel R. Passeri, Curis' President and Chief Executive Officer, will provide a presentation that includes an overview of the status of GDC-0449, an orally-administered small molecule inhibitor of the Hedgehog pathway that is currently in Phase II clinical testing under collaboration with Genentech. Mr. Passeri will also discuss CUDC-101, CUDC-305 and Curis' other targeted cancer programs in addition to other corporate activities. There will also be a corresponding webcast of the presentation, which can be accessed by visiting:
http://www.wsw.com/webcast/mcm10/cris/
The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will also be available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its targeted cancer drug development platform, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.
CONTACT: Curis, Inc.
Michael P. Gray, 617-503-6632
CFO & COO
mgray@curis.com
SOURCE: Curis, Inc.